File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The development of an AIDS mucosal vaccine

TitleThe development of an AIDS mucosal vaccine
Authors
KeywordsAids
Hiv-1
Mucosal vaccination
Mvtt
Vaccine
Issue Date2010
PublisherMolecular Diversity Preservation International (MDPI) AG.. The Journal's web site is located at http://www.mdpi.com/journal/viruses
Citation
Viruses, 2010, v. 2 n. 1, p. 283-297 How to Cite?
AbstractIt is well known that mucosal tissues contain the largest surface area of the human body and are the front line of natural host defense against various pathogens. In fact, more than 80% of infectious disease pathogens probably gain entry into the susceptible human hosts through open mucosal surfaces. Human immunodeficiency virus type one (HIV-1), a mainly sexually transmitted virus, also primarily targets the vaginal and gastrointestinal mucosa as entry sites for viral transmission, seeding, replication and amplification. Since HIV-1 establishes its early replication in vaginal or rectal mucosal tissues, the induction of sufficient mucosal immunity at the initial site of HIV-1 transmission becomes essential for a protective vaccine. However, despite the fact that current conventional vaccine strategies have remained unsuccessful in preventing HIV-1 infection, sufficient financial support and resources have yet to be given to develop a vaccine able to elicit protective mucosal immunity against sexual transmissions. Interestingly, Chinese ancestors invented variolation through intranasal administration about one thousand years ago, which led to the discovery of a successful smallpox vaccine and the final eradication of the disease. It is the hope for all mankind that the development of a mucosal AIDS vaccine will ultimately help control the AIDS pandemic. In order to discover an effective mucosal AIDS vaccine, it is necessary to have a deep understanding of mucosal immunology and to test various mucosal vaccination strategies. © 2010 by the authors.
Persistent Identifierhttp://hdl.handle.net/10722/129302
ISSN
2015 Impact Factor: 3.042
2015 SCImago Journal Rankings: 1.873
PubMed Central ID
ISI Accession Number ID
Funding AgencyGrant Number
Hong Kong research grant councilHK-RGC762208
HK-RGC762209
National Science and Technology Major Programs2008ZX10001-011
2008ZX10001-015
University of Hong Kong
Funding Information:

The authors thank financial supports from Hong Kong research grant council (HK-RGC762208 and HK-RGC762209 to ZC), the National Science and Technology Major Programs (2008ZX10001-011 and 2008ZX10001-015) and the University Development Fund of the University of Hong Kong to its AIDS Institute. The authors also thank D.D. Ho and K.Y. Yuen for scientific advice and discussions.

References

 

DC FieldValueLanguage
dc.contributor.authorTang, Xen_HK
dc.contributor.authorChen, Zen_HK
dc.date.accessioned2010-12-23T08:34:57Z-
dc.date.available2010-12-23T08:34:57Z-
dc.date.issued2010en_HK
dc.identifier.citationViruses, 2010, v. 2 n. 1, p. 283-297en_HK
dc.identifier.issn1999-4915en_HK
dc.identifier.urihttp://hdl.handle.net/10722/129302-
dc.description.abstractIt is well known that mucosal tissues contain the largest surface area of the human body and are the front line of natural host defense against various pathogens. In fact, more than 80% of infectious disease pathogens probably gain entry into the susceptible human hosts through open mucosal surfaces. Human immunodeficiency virus type one (HIV-1), a mainly sexually transmitted virus, also primarily targets the vaginal and gastrointestinal mucosa as entry sites for viral transmission, seeding, replication and amplification. Since HIV-1 establishes its early replication in vaginal or rectal mucosal tissues, the induction of sufficient mucosal immunity at the initial site of HIV-1 transmission becomes essential for a protective vaccine. However, despite the fact that current conventional vaccine strategies have remained unsuccessful in preventing HIV-1 infection, sufficient financial support and resources have yet to be given to develop a vaccine able to elicit protective mucosal immunity against sexual transmissions. Interestingly, Chinese ancestors invented variolation through intranasal administration about one thousand years ago, which led to the discovery of a successful smallpox vaccine and the final eradication of the disease. It is the hope for all mankind that the development of a mucosal AIDS vaccine will ultimately help control the AIDS pandemic. In order to discover an effective mucosal AIDS vaccine, it is necessary to have a deep understanding of mucosal immunology and to test various mucosal vaccination strategies. © 2010 by the authors.en_HK
dc.languageengen_US
dc.publisherMolecular Diversity Preservation International (MDPI) AG.. The Journal's web site is located at http://www.mdpi.com/journal/virusesen_HK
dc.relation.ispartofVirusesen_HK
dc.subjectAidsen_HK
dc.subjectHiv-1en_HK
dc.subjectMucosal vaccinationen_HK
dc.subjectMvtten_HK
dc.subjectVaccineen_HK
dc.titleThe development of an AIDS mucosal vaccineen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1999-4915&volume=2&issue=1&spage=283&epage=297&date=2010&atitle=The+development+of+an+AIDS+mucosal+vaccine-
dc.identifier.emailChen, Z:zchenai@hkucc.hku.hken_HK
dc.identifier.authorityChen, Z=rp00243en_HK
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3390/v2010283en_HK
dc.identifier.pmid21994611-
dc.identifier.pmcidPMC3185548-
dc.identifier.scopuseid_2-s2.0-79952083300en_HK
dc.identifier.hkuros176629en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-79952083300&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume2en_HK
dc.identifier.issue1en_HK
dc.identifier.spage283en_HK
dc.identifier.epage297en_HK
dc.identifier.isiWOS:000280413300016-
dc.publisher.placeSwitzerlanden_HK
dc.identifier.scopusauthoridTang, X=36143652700en_HK
dc.identifier.scopusauthoridChen, Z=35271180800en_HK
dc.identifier.citeulike6581465-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats